Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-3122024-01-01false3falsefalsefalse 07857151 2024-01-01 2024-12-31 07857151 2023-01-01 2023-12-31 07857151 2024-12-31 07857151 2023-12-31 07857151 c:Director3 2024-01-01 2024-12-31 07857151 c:Director4 2024-01-01 2024-12-31 07857151 c:Director4 2024-12-31 07857151 c:Director5 2024-01-01 2024-12-31 07857151 c:RegisteredOffice 2024-01-01 2024-12-31 07857151 d:CurrentFinancialInstruments 2024-12-31 07857151 d:CurrentFinancialInstruments 2023-12-31 07857151 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 07857151 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 07857151 d:UKTax 2024-01-01 2024-12-31 07857151 d:UKTax 2023-01-01 2023-12-31 07857151 d:ShareCapital 2024-12-31 07857151 d:ShareCapital 2023-12-31 07857151 d:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 07857151 d:RetainedEarningsAccumulatedLosses 2024-12-31 07857151 d:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 07857151 d:RetainedEarningsAccumulatedLosses 2023-12-31 07857151 d:RetainedEarningsAccumulatedLosses 2023-01-01 07857151 c:FRS102 2024-01-01 2024-12-31 07857151 c:Audited 2024-01-01 2024-12-31 07857151 c:FullAccounts 2024-01-01 2024-12-31 07857151 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 07857151 e:PoundSterling 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure
Registered number: 07857151


 
 
 
 
 
 
NXSTAGE MEDICAL UK, LTD.

DIRECTORS' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

 
NXSTAGE MEDICAL UK, LTD.
 

COMPANY INFORMATION


Directors
Laura Bell 
Christopher James Slater 




Registered number
07857151



Registered office
Nunn Brook Road
Huthwaite

Sutton-In-Ashfield

Nottinghamshire

NG17 2HU




Independent auditors
Wilder Coe Ltd
Chartered Accountants & Statutory Auditors

1st Floor Sackville House

143-149 Fenchurch Street

London

EC3M 6BL





 
NXSTAGE MEDICAL UK, LTD.
 

CONTENTS



Page
Directors' Report
 
1 - 2
Independent Auditors' Report
 
3 - 6
Statement of Income and Retained Earnings
 
7
Balance Sheet
 
8
Notes to the Financial Statements
 
9 - 15


 
NXSTAGE MEDICAL UK, LTD.
 

 
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024

The directors present their report and the audited financial statements for the year ended 31 December 2024.

Directors' responsibilities statement

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.
 
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

 In preparing these financial statements, the directors are required to:


select suitable accounting policies for the Company's financial statements and then apply them consistently;

make judgments and accounting estimates that are reasonable and prudent; and

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Principal activity

The company has changed its principal activity from the promotion, sale and distribution of renal care products manufactured by the group within the United Kingdom to acting as a financier for the Fresenius Group.

Directors

The directors who served during the year were:

Laura Bell 
Antony Mazzei (resigned 10 December 2024)
Christopher James Slater 

Disclosure of information to auditors

Each of the persons who are directors at the time when this Directors' Report is approved has confirmed that:
 
so far as the director is aware, there is no relevant audit information of which the Company's auditors are unaware, and

the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditors are aware of that information.

Page 1

 
NXSTAGE MEDICAL UK, LTD.
 

 
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024


Auditors

The auditorsWilder Coe Ltdwill be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

This report was approved by the board on 13 June 2025 and signed on its behalf.
 





Laura Bell
Director

Page 2

 
NXSTAGE MEDICAL UK, LTD.
 

 
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NXSTAGE MEDICAL UK, LTD.
 

Opinion


We have audited the financial statements of Nxstage Medical UK, Ltd. (the 'Company') for the year ended 31 December 2024, which comprise the Statement of Income and Retained Earnings, the Balance Sheet and the related notes, including a summary of significant accounting policiesThe financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).


In our opinion the financial statements:


give a true and fair view of the state of the Company's affairs as at 31 December 2024 and of its loss for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.


Basis for Opinion


We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.


Conclusions relating to going concern


In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.


Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.


Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.


Other information


The other information comprises the information included in the Annual Report other than the financial statements and our Auditors' Report thereon. The directors are responsible for the other information contained within the Annual ReportOur opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.


We have nothing to report in this regard.


Page 3

 
NXSTAGE MEDICAL UK, LTD.
 

 
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NXSTAGE MEDICAL UK, LTD. (CONTINUED)


Opinion on other matters prescribed by the Companies Act 2006
 

In our opinion, based on the work undertaken in the course of the audit:


the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the Directors' Report has been prepared in accordance with applicable legal requirements.


Matters on which we are required to report by exception
 

In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors' Report.


We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:


adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit; or
the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption from the requirement to prepare a Strategic Report.


Responsibilities of directors
 

As explained more fully in the Directors' Responsibilities Statement set out on page 1, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.


In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.


Page 4

 
NXSTAGE MEDICAL UK, LTD.
 

 
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NXSTAGE MEDICAL UK, LTD. (CONTINUED)


Auditors' responsibilities for the audit of the financial statements
 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.


Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Discussions with and enquiries of management and those charged with governance were held with a view to identifying those laws and regulations that could be expected to have a material impact on the financial statements. During the engagement team briefing, the outcomes of these discussions and enquiries were shared with the team, as well as consideration as to where and how fraud may occur in the entity.
The following laws and regulations were identified as being of significance to the entity:
 
Those laws and regulations considered to have a direct effect on the financial statements include UK financial reporting standards, company law, tax and pensions legislation and distibutable profits legislation; and 
Those laws and regulations for which non-compliance may be fundamental to the operating aspects of the business and therefore may have a material effect on the financial statements.

Audit procedures undertaken in response to the potential risks relating to irregularities (which include fraud and
non-compliance with laws and regulations) comprised of: enquiries of management and those charged with
governance as to whether the entity complies with such laws and regulations; enquiries with the same
concerning any actual or potential litigation or claims; inspection of relevant legal correspondence; review of
board minutes; testing the appropriateness of journal entries; and the performance of analytical review to
identify unexpected movements in account balances which may be indicative of fraud.
Where irregularities have been found and treatments have differed from what we have expected additional
procedures have been conducted to ratify the discrepancies. If the irregularity is financial in nature then samples
have been extended, and the irregular items extrapolated to ensure that no material misstatement has
occurred. These irregularities are also communicated to management so that they can rectify the discrepancies
or provide an explanation for the difference. Where the irregularity is a difference in treatment to what we had
expected this has been communicated to management and additional explanation has been added ensure
adequate disclosure where necessary.
No instances of material non-compliance were identified. However, the likelihood of detecting irregularities,
including fraud, is limited by the inherent difficulty in detecting irregularities, the effectiveness of the entity’s
controls, and the nature, timing and extent of the audit procedures performed. Irregularities that result from
fraud might be inherently more difficult to detect than irregularities that result from error. As explained above,
there is an unavoidable risk that material misstatements may not be detected, even though the audit has been
planned and performed in accordance with ISAs (UK).


A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' Report.


Page 5

 
NXSTAGE MEDICAL UK, LTD.
 

 
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NXSTAGE MEDICAL UK, LTD. (CONTINUED)


Use of our report
 

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.





Caryl King BSc ACA (Senior Statutory Auditor)
for and on behalf of
 

 
Wilder Coe Ltd
Chartered Accountants & Statutory Auditors
1st Floor Sackville House
143-149 Fenchurch Street
London
EC3M 6BL
 

Date: 16 June 2025
Page 6

 
NXSTAGE MEDICAL UK, LTD.
 

STATEMENT OF INCOME AND RETAINED EARNINGS
FOR THE YEAR ENDED 31 DECEMBER 2024

2024
2023
Note
£
£

  

Turnover
  
-
8,869,869

Cost of sales
  
(9,570)
(9,506,835)

Gross loss
  
(9,570)
(636,966)

Administrative expenses
  
(205,441)
701,812

Operating (loss)/profit
  
(215,011)
64,846

Interest payable and similar expenses
  
(30,534)
-

(Loss)/profit on ordinary activities before taxation
  
(245,545)
64,846

Tax on (loss)/profit on ordinary activities
 5 
-
(115,087)

Loss for the financial year
  
(245,545)
(50,241)

Retained earnings at the beginning of the year
  
1,738,619
1,788,860

Loss for the year
  
(245,545)
(50,241)

Retained earnings at the end of the year
  
1,493,074
1,738,619

The notes on pages 9 to 15 form part of these financial statements.

Page 7

 
NXSTAGE MEDICAL UK, LTD.
REGISTERED NUMBER: 07857151

BALANCE SHEET
AS AT 31 DECEMBER 2024

2024
2023
Note
£
£

  

Current assets
  

Debtors
 6 
2,772,613
6,416,448

Cash at bank and in hand
  
53,961
135,141

  
2,826,574
6,551,589

Creditors: amounts falling due within one year
 7 
(16,050)
(3,495,520)

  

Net assets
  
2,810,524
3,056,069


Capital and reserves
  

Allotted, called up and fully paid share capital
  
1,317,450
1,317,450

Profit and loss account
  
1,493,074
1,738,619

Equity shareholders' funds
  
2,810,524
3,056,069


The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 13 June 2025.




Laura Bell
Director

The notes on pages 9 to 15 form part of these financial statements.

Page 8

 
NXSTAGE MEDICAL UK, LTD.
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.


General information

NxStage Medical UK, Ltd. (Company number: 07857151), having its registered office and principal place of business at Nunn Brook Road, Huthwaite, Sutton-In-Ashfield, Nottinghamshire, NG17 2HU, is a private limited company incorporated in England and Wales.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

  
2.2

Statement of Cash Flows

The Company has taken advantage of the exemption in Financial Reporting Standard 102, Section 1.12 from the requirement to provide a Statement of Cash Flows on the grounds that it is a qualifying entity and the ultimate parent prepares consolidated group accounts. 

 
2.3

Turnover

Turnover is recognised when the risks and rewards associated with the provision of treatments has substantially transferred, in accordance with the contract with the respective healthcare body. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before turnover is recognised:

Sale of goods

Turnover from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of turnover can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Turnover from a contract to provide services is recognised in the period in which the services are provided when all of the following conditions are satisfied:
the amount of turnover can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 9

 
NXSTAGE MEDICAL UK, LTD.
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.4

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings

The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Balance Sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of premanent differences. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.


 
2.5

Debtors

Short-term debtors are measured at transaction price, less any impairment.

 
2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.

 
2.7

Creditors

Short-term creditors are measured at the transaction price.

 
2.8

Foreign currency translation

Functional and presentation currency
The Company's functional and presentational currency is British Pound Sterling (GBP).
Transactions and balances
Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.
At each period-end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.
Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Income and Retained Earnings.

Page 10

 
NXSTAGE MEDICAL UK, LTD.
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.9

Financial instruments


The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.
Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received.

  
2.10

Provisions for liabilities

Provisions are made where an event has taken place that gives the Company a legal or constructive
obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate
can be made of the amount of the obligation.
Provisions are charged as an expense to the Statement of Income and Retained Earnings in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the Balance Sheet date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.
When payments are eventually made, they are charged to the provision carried in the Balance Sheet.
Provisions are recognised when an event has taken place that gives rise to a legal or constructive
obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking
into account the related risks and uncertainties.
Increases in provisions are generally charged as an expense to the Statement of Income and Retained Earnings.


3.


Judgments in applying accounting policies and key sources of estimation uncertainty

In the application of the Company's accounting policies the Directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. These estimates and assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of the revision and future periods if the revision affects both current and future periods. 

Page 11

 
NXSTAGE MEDICAL UK, LTD.
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

4.


Employees


The average monthly number of employees, including the directors, during the year was as follows:


        2024
        2023
            No.
            No.







Employees
3
2

Page 12

 
NXSTAGE MEDICAL UK, LTD.
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

5.


Taxation


2024
2023
£
£

Corporation tax


Current tax on loss/profit for the year
-
431,739


Deferred tax


Origination and reversal of timing differences
-
(316,652)


Taxation on profit on ordinary activities
-
115,087

Factors affecting tax charge for the year

The tax assessed for the year is higher than (2023 - higher than)  the standard rate of corporation tax in the UK of 25% (2023 - 25%). The differences are explained below:

2024
2023
£
£


(Loss)/profit on ordinary activities before tax
(245,545)
64,846


(Loss)/profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 25% (2023 - 25%)
(61,386)
16,212

Effects of:


Effect of a change in tax rates
-
(27,158)

Capital allowances for year in excess of depreciation
-
107,159

Balancing charges
-
519,915

Profit on disposal of fixed assets
-
(184,389)

Deferred tax charge
-
(316,652)

Creation of tax losses
61,386
-

Total tax charge for the year
-
115,087


Factors that may affect future tax charges

As at 31 December 2024, the Company had trading losses of £245,545 (2023: £Nil) available to carry forward and offset against future taxable profits.
 

Page 13

 
NXSTAGE MEDICAL UK, LTD.
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

6.


Debtors

2024
2023
£
£


Trade debtors
118,598
593,267

Amounts owed by group undertakings
2,509,116
5,812,654

Other debtors
144,899
10,527

2,772,613
6,416,448



7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
5,700
5,700

Amounts owed to group undertakings
-
2,395,189

Corporation tax
-
431,739

Other taxation and social security
-
646,296

Other creditors
-
596

Accruals and deferred income
10,350
16,000

16,050
3,495,520



8.


Deferred taxation

2024
2023
£
£



At beginning of year
-
(442,684)

Charged to profit or loss
-
442,684

At end of year
-
-


9.


Related party transactions

The Company has taken advantage of Section 33.1A of FRS 102 in not disclosing transactions between wholly-owned members of a group.

Page 14

 
NXSTAGE MEDICAL UK, LTD.
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

10.


Immediate parent undertaking

As at 31 December 2024 and 31 December 2023, the immediate parent undertaking was Fresenius Medical Care (Holdings) Ltd.
The parents registered address is:
Nunn Brook Road, 
Huthwaite, Sutton In Ashfield, 
Nottinghamshire, NG17 2HU


11.


Ultimate parent undertaking

As at 31 December 2024 and 31 December 2023, the ultimate parent undertaking was Fresenius Medical Care AG & Co. KGaA, a listed company incorporated in Germany.
Consolidated financial statements are available from the following address:
Else-Kröner-Straße 1,
61352 Bad Homburg v.d. Höhe,
Germany


Page 15